LPCN
Lipocine Inc.
Set alert
- YTD
- -82.07%
- 1 year
- -44.62%
- Open
- 1.50
- Prev close
- 1.52
- Mkt cap
- 11.87M
- Vol
- 112.05K
- Avg vol
- 1.80M
- EPS
- -1.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.42
- High
- 1.50
- Forward P/E
- -3.87
- Beta
- 1.19
- Short ratio
- 2.80
- Inst. own
- 9.96%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.16
- 200-d avg
- 5.39
- 1y target
- 21.50
Key statistics
- Market cap
- 25.67M
- Enterprise value
- 10.11M
- Trailing P/E
- 0.00
- Forward P/E
- -3.87
- PEG ratio
- 0.00
- Price / sales
- 5.35
- Price / book
- 1.25
- EPS (TTM)
- -0.75
- Beta
- 1.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -176.80%
- Revenue (TTM)
- 4.80M
- Revenue growth
- 0.00%
- Free cash flow
- -4.61M
- Total cash
- 22.55M
- Total debt
- 245.38K
- Return on equity
- -34.12%
- Shares outstanding
- 5.35M
- Short % of float
- 2.07%
- 50-day average
- 5.16
- 200-day average
- 5.39
Analyst view
Consensus: none
- Target (low)
- 10.00
- Target (mean)
- 21.50
- Target (high)
- 33.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.44 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.56 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | 0.66 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.53 | -0.42 | +0.11 | +20.75% |
| Nov 8, 2023 | Sep 1, 2023 | -0.57 | -1.27 | -0.70 | -122.81% |
| Aug 10, 2023 | Jun 1, 2023 | -0.64 | -0.68 | -0.04 | -6.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 27, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lipocine.com
News
- Nasdaq Falls Over 100 Points; US Crude Inventories Decline
- Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
- Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males
- HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
- Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
- Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26
- CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate
- What's Going On With Carvana Stock Monday?
Your note
Sign in to keep a note on LPCN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FOGARTY KRISTA | Officer | Stock Award(Grant) | Mar 7, 2024 | 1,727 |
| ONO RICHARD DANA | Director | Purchase | Mar 19, 2023 | 14,125 |
| PATEL MAHESH V | Chief Executive Officer | Stock Award(Grant) | Mar 7, 2024 | 112,311 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.14% | 221,459 | 1.06M | Sep 29, 2024 |
| Blackrock Inc. | 1.67% | 89,272 | 428.50K | Sep 29, 2024 |
| UBS Group AG | 1.11% | 59,413 | 285.18K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.01% | 54,216 | 260.24K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.75% | 40,332 | 193.59K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.47% | 25,008 | 120.04K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.64% | 141,076 | 677.16K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 74,283 | 356.56K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.57% | 30,478 | 146.29K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 8,765 | 42.07K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.14% | 7,261 | 34.85K | Jul 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 7,542 | 36.20K | Oct 30, 2024 |